| Name | Title | Contact Details |
|---|---|---|
John Lamoureux |
Director, Global IT Infrastructure and Security | Profile |
OnKure, Inc. is a biopharmaceutical company focused on the discovery and development of targeted small molecule drugs to improve the outcomes of patients afflicted with cancer. OnKure`s drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized.
Canderm Pharma, Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company`s dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy.
Ionwerks is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
IM Cannabis (IMC) is one of the world`s pioneering medical-grade cannabis companies, with operations in Israel, across Europe, and Canada. Over the past decade, IMC has established its premium medical cannabis brand, comprising a full spectrum of products known for their quality, consistency, and purity, such as ROMA, TEL AVIV and LONDON. In Europe, IMC has established a fully operational, vertically integrated medical cannabis business, spearheaded by its EU-GMP certified distribution arm in Germany and augmented by strategic alliances with certified pan-EUGMP certified suppliers. To this end, IMC has formed strong strategic alliances within the international medical cannabis industry, aiming for a dominant position in satisfying the global demand for high-quality medical cannabis products, which both physicians and patients can rely upon. IMC further intends to leverage its expertise in Israel in order to bolster its research and development initiative while collaborating with world-renowned scientists on cutting-edge technology for the benefit of patients around the world